Sleeve Gastrectomy Improves Metabolic Health, Cognition, and Alzheimer's Disease Pathology in 3xTG Mice.
6 affiliations
- 1Wisconsin Surgical Laboratory in Metabolism, Department of Surgery, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- 2William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
- 3Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- 4Laboratory of Genetics, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- 5University of Wisconsin-Madison Comprehensive Diabetes Center, Madison, Wisconsin, USA.
- 6Wisconsin Nathan Shock Center of Excellence in the Basic Biology of Aging, Madison, Wisconsin, USA.
Abstract
Obesity and diabetes are well-established risk factors for Alzheimer's disease (AD), implicating metabolic dysfunction in AD pathogenesis. Sleeve gastrectomy (SG) is among the most effective metabolic interventions available, yet its impact on AD progression remains poorly understood. We hypothesized that SG performed early in life would improve metabolic health, attenuate AD pathology, and preserve cognition in a transgenic AD mouse model. Five-week-old female 3xTg-AD mice were preconditioned on a Western diet (WD) to induce obesity and glucose intolerance, then randomized to SG or sham surgery and maintained on either Control or continued WD for 12 months. Metabolic phenotyping, body composition, and cognitive assessments (Novel Object Recognition, Barnes Maze, Fear Conditioning) were performed longitudinally, with histological and molecular brain analysis at endpoint. Under Control-fed conditions, SG reduced fat mass and improved peripheral insulin sensitivity independent of food intake. These changes were accompanied by reduced cortical Aβ plaque burden and attenuated astrocytic (GFAP) and microglial (IBA1) activation, specifically in the cortex. Mechanistically, SG altered the insulin signaling-autophagy axis in a region-specific manner, with increased pAKT and suppressed ATG5/ATG7/ATG16L1 in the cortex. Under persistent WD, SG improved glucose homeostasis, reduced fat mass, lowered frailty, and rescued short- and long-term spatial memory deficits in the Barnes maze, accompanied by reduced cortical Aβ burden. Collectively, these findings provide the first preclinical evidence that SG attenuates AD progression through a brain insulin signaling-autophagy axis, supporting metabolic surgery as a promising disease-modifying intervention for AD prevention in individuals with obesity.
Related
- A First-in-Class, Brain-Penetrant Small Molecule Inhibitor of the NOS1AP-Tau Interaction Rescues Tau Pathology In Vivo and Improves Cognition
- Association of neighborhood deprivation with Alzheimer's disease pathology, brain structure, and cognition by race and ethnicity, sex, and APOE ε4 status.
- Alzheimer's disease risk gene Wwox controls amyloid pathology through metabolic reprogramming.
- Small-Nerve Fibre Pathology in Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Liver Fat/Inflammation and Improves with Weight Loss
- Tirzepatide for Weight Recurrence After Metabolic and Bariatric Surgery: A Critical Review of Direct and Indirect Evidence with Emphasis on Sleeve Gastrectomy, Nutritional Safety, and Clinical Implications
BibTeX
@article{babygirija2026sleeve,
title = {{Sleeve Gastrectomy Improves Metabolic Health, Cognition, and Alzheimer's Disease Pathology in 3xTG Mice.}},
author = {Reji Babygirija and Julia A Illiano and Michelle M Sonsalla and Grace Zhu and Christopher Retter Jabbarpour and Twinkle Mathew and Tristan Molkentin and Meredith Peterson and Carolyn Winder and Advaith Ravi Krishnan Nair and Fan Xiao and Justin M Wolter and Dudley W Lamming and David A Harris},
journal = {Aging cell},
year = {2026},
month = oct,
doi = {10.1111/acel.70767},
url = {https://europepmc.org/article/MED/42867481},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sleeve Gastrectomy Improves Metabolic Health, Cognition, and Alzheimer's Disease Pathology in 3xTG Mice.
AU - Reji Babygirija
AU - Julia A Illiano
AU - Michelle M Sonsalla
AU - Grace Zhu
AU - Christopher Retter Jabbarpour
AU - Twinkle Mathew
AU - Tristan Molkentin
AU - Meredith Peterson
AU - Carolyn Winder
AU - Advaith Ravi Krishnan Nair
AU - Fan Xiao
AU - Justin M Wolter
AU - Dudley W Lamming
AU - David A Harris
PY - 2026
DA - 2026/10/01
JO - Aging cell
DO - 10.1111/acel.70767
UR - https://europepmc.org/article/MED/42867481
AB - Obesity and diabetes are well-established risk factors for Alzheimer's disease (AD), implicating metabolic dysfunction in AD pathogenesis. Sleeve gastrectomy (SG) is among the most effective metabolic interventions available, yet its impact on AD progression remains poorly understood. We hypothesized that SG performed early in life would improve metabolic health, attenuate AD pathology, and preserve cognition in a transgenic AD mouse model. Five-week-old female 3xTg-AD mice were preconditioned on a Western diet (WD) to induce obesity and glucose intolerance, then randomized to SG or sham surgery and maintained on either Control or continued WD for 12 months. Metabolic phenotyping, body composition, and cognitive assessments (Novel Object Recognition, Barnes Maze, Fear Conditioning) were performed longitudinally, with histological and molecular brain analysis at endpoint. Under Control-fed conditions, SG reduced fat mass and improved peripheral insulin sensitivity independent of food intake. These changes were accompanied by reduced cortical Aβ plaque burden and attenuated astrocytic (GFAP) and microglial (IBA1) activation, specifically in the cortex. Mechanistically, SG altered the insulin signaling-autophagy axis in a region-specific manner, with increased pAKT and suppressed ATG5/ATG7/ATG16L1 in the cortex. Under persistent WD, SG improved glucose homeostasis, reduced fat mass, lowered frailty, and rescued short- and long-term spatial memory deficits in the Barnes maze, accompanied by reduced cortical Aβ burden. Collectively, these findings provide the first preclinical evidence that SG attenuates AD progression through a brain insulin signaling-autophagy axis, supporting metabolic surgery as a promising disease-modifying intervention for AD prevention in individuals with obesity.
SN - 1474-9718
SN - 1474-9726
ER -